GSKs Gepotidacin A Potential Game Changer in the Fight Against Gonorrhea
GSK's groundbreaking gepotidacin, an innovative oral antibiotic, has unveiled exciting findings in the EAGLE-1 phase 3 trial focusing on uncomplicated ...
© 2024 Stocks Today
Tag: GSK
Groundbreaking Phase 1b2 Clinical Trial Explores the Potential of LB100 and Dostarlimabgxly for Ovarian Clear Cell Carcinoma
Lixte Biotechnology, a leading biotech company, has recently commenced a groundbreaking Phase 1b/2 clinical trial on January 29, 2024. This ...
Elegen and GSK Enter Groundbreaking Collaboration and Licensing Agreement for CellFree DNA Technology
On January 24, 2024, a groundbreaking collaboration and licensing agreement was signed between Elegen and GSK. This agreement allows GSK ...
Major Regulatory Milestones for Cabotegravir LongActing as HIV PrEP
On January 10, 2024, ViiV Healthcare, in collaboration with Pfizer and Shionogi, submitted a new drug application to Health Canada ...
What Investors Should Know About Old Port Advisors’ Increased Stake in GSK Plc
Old Port Advisors Increases Stake in GSK Plc: What This Means for Investors In a recent Form 13F filing with ...
Popular News
-
Exploring the Rise of AI in Empowering Business and Personal Growth: Trends and Innovations
-
Unlocking the Future: The Rise of Open-Source FPGA Development Tools
-
The Future of Secure Communications: How Quantum-Resistant Encryption is Revolutionizing Wireless Technology
-
The Booming Market of Plant-Based Pharmaceuticals for Neurological Conditions
-
Unlocking Potential: How Recent Acquisitions in the Battery Technology Sector Are Reshaping the Energy Landscape